Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer

doi:10.3877/cma.j.issn.1674-3946.2023.03.004

Abstract

Abstract:

The first choice of treatment for de novo stage Ⅳ breast cancer is systemic therapy based on molecular typing. Thanks to the rapid iteration of new anti-cancer drugs and the popularization of clinical application of genetic testing tools，the survival time and quality of life of patients with de novo stage Ⅳ breast cancer have been greatly improved，and the principles of local surgical treatment have become a hot issue of clinical concern. Based on this，the Chinese Society of Breast Surgery took the lead and conducted a discussion on the key issues in the diagnosis and treatment of de novo stage Ⅳ breast cancer，developed the clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer（2022 edtition）.

Key words: De novo stage Ⅳ breast cancer, Surgical procedures, operative, Guidebooks

Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2023.03.004

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2023/V17/I03/250

References 47

[1]	Siegel RL，Miller KD，Fuchs HE，et al. Cancer Statistics，2021［J］. CA Cancer J Clin，2021，71（1）：7-33.
[2]	Zheng A，Guo BL，Zhang JG，et al. Clinical information and management status of de novo stage Ⅳ breast cancer patients：a Chinese multicenter investigation（CSBrS-002）［J］. Chin Med J（Engl），2021，134（13）：1569-1575.
[3]	Malmgren JA，Mayer M，Atwood MK，et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time：1990-2010［J］. Breast Cancer Res Treat，2018，167（2）：579-590.
[4]	Giuliano AE，Edge SB，Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual：Breast Cancer［J］. Ann Surg Oncol，2018，25（7）：1783-1785.
[5]	国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会，中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南（2020版）［J］. 中华肿瘤杂志，2020，42（10）：781-797.
[6]	Gradishar WJ，Moran MS，Abraham J，et al. NCCN Guidelines® Insights：Breast Cancer，Version 4.2021［J］. J Natl Compr Canc Netw，2021，19（5）：484-493.
[7]	Tagliafico AS，Piana M，Schenone D，et al. 2020. Overview of radiomics in breast cancer diagnosis and prognostication［J］. Breast，49：74-80.
[8]	Zheng C，Yu ZG. Clinical practice guidelines for pre-operative evaluation of breast cancer：Chinese Society of Breast Surgery（CSBrS）practice guidelines 2021［J］. Chin Med J（Engl），2021，134（18）：2147-2149.
[9]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南2021［M］. 北京：人民卫生出版社，2021.
[10]	Expert Panel on Breast Imaging，Slanetz PJ，Moy L，et al. ACR Appropriateness Criteria（®）Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer［J］. J Am Coll Radiol，2017，14（11S）：S462-S475.
[11]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤（CSCO）中枢神经系统转移性肿瘤诊疗指南2021［M］，北京：人民卫生出版社，2021.
[12]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范（2021年版）［J］. 中国癌症杂志，2021，31（10）：954-1040.
[13]	Constantinidou A，Martin A，Sharma B，et al. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer：a large retrospective study from the Royal Marsden Hospital［J］. Ann Oncol，2011，22（2）：307-314.
[14]	Eubank WB，Mankoff D，Bhattacharya M，et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer［J］. AJR Am J Roentgenol，2004，183（2）：479-486.
[15]	向泓雨，刘倩，刘荫华. 2021版《中华医学会乳腺外科临床实践指南》重点内容解读［J］. 中国实用外科杂志，2021，41（11）：1257-1261.
[16]	Tarantino P，Gandini S，Nicolò E，et al. 2022. Evolution of low HER2 expression between early and advanced-stage breast cancer［J］. Eur J Cancer，163：35-43.
[17]	Modi S，Jacot W，Yamashita T，et al. 2022. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer［J］. N Engl J Med，387：9-20.
[18]	Robson ME，Tung N，Conte P，et al. OlympiAD final overall survival and tolerability results：Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer［J］. Ann Oncol，2019，30（4）：558-566.
[19]	Jr Geyer CE，Garber JE，Gelber RD，et al. 2022. Overall survival in the OlympiA phase Ⅲ trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk，early breast cancer［J］. Ann Oncol，2022，33（12）：1250-1268.
[20]	向泓雨，刘荫华. 2022年《中华医学会乳腺外科临床实践指南》更新解读［J］. 中国肿瘤外科杂志，2022，14（03）：219-223.
[21]	Price DD，Mcgrath PA，Rafii A，et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain［J］. Pain，1983，17（1）：45-56.
[22]	lane WO，thomas SM，blitzblau RC，et al. Surgical Resection of the Primary Tumor in Women With De Novo Stage Ⅳ Breast Cancer：Contemporary Practice Patterns and Survival Analysis［J］. Ann Surg，2019，269（3）：537-544.
[23]	Si Y，Yuan P，Hu N，et al. Primary Tumor Surgery for Patients with De Novo Stage Ⅳ Breast Cancer can Decrease Local Symptoms and Improve Quality of Life［J］. Ann Surg Oncol，2020，27（4）：1025-1033.
[24]	Soran A，Ozmen V，Ozbas S，et al. Primary Surgery with Systemic Therapy in Patients with de Novo Stage Ⅳ Breast Cancer：10-year Follow-up；Protocol MF07-01 Randomized Clinical Trial［J］. J Am Coll Surg，2021，233（6）：742-751.e5.
[25]	King TA，Lyman JP，Gonen M，et al. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage Ⅳ Breast Cancer：TBCRC 013［J］. J Clin Oncol，2016，34（20）：2359-2365.
[26]	Khan SA，Zhao F，Goldstein LJ，et al. Early Local Therapy for the Primary Site in De Novo Stage Ⅳ Breast Cancer：Results of a Randomized Clinical Trial（EA2108）［J］. J Clin Oncol，2022，40（9）：978-987.
[27]	Rao R，Feng L，Kuerer HM，et al. Timing of surgical intervention for the intact primary in stage Ⅳ breast cancer patients［J］. Ann Surg Oncol，2008，15（6）：1696-1702.
[28]	Ruiterkamp J，Ernst MF，van de Poll-Franse LV，et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis［J］. Eur J Surg Oncol，2009，35（11）：1146-1151.
[29]	Pathy NB，Verkooijen HM，Taib NA，et al. Impact of breast surgery on survival in women presenting with metastatic breast cancer［J］. Br J Surg，2011，98（11）：1566-1572.
[30]	Rapiti E，Verkooijen HM，Vlastos G，et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis［J］. J Clin Oncol，2006，24（18）：2743-2749.
[31]	Cardoso F，Paluch-Shimon S，Senkus E，et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer（ABC 5）［J］. Ann Oncol，2020，31（12）：1623-1649.
[32]	Friedel G，Pastorino U，Ginsberg RJ，et al. Results of lung metastasectomy from breast cancer：prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases［J］. Eur J Cardiothorac Surg，2002，22（3）：335-344.
[33]	Abbott DE，Brouquet A，Mittendorf EA，et al. Resection of liver metastases from breast cancer：estrogen receptor status and response to chemotherapy before metastasectomy define outcome［J］. Surgery，2012，151（5）：710-716.
[34]	Bilani N，Yaghi M，Main O，et al. Metastasectomy versus radiation of secondary sites in stage Ⅳ breast cancer：Analysis from a national cancer registry［J］. Breast，2021，60：185-191.
[35]	Fan J，Chen D，Du H，et al. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients：a systematic review and meta-analysis［J］. J Thorac Dis，2015，7（8）：1441-1451.
[36]	Feng Y，He XG，Zhou CM，et al. Comparison of hepatic resection and systemic treatment of breast cancer liver metastases：A propensity score matching study［J］. Am J Surg，2020，220（4）：945-951.
[37]	Ercolani G，Zanello M，Serenari M，et al. Ten-Year Survival after Liver Resection for Breast Metastases：A Single-Center Experience［J］. Dig Surg，2018，35（4）：372-380.
[38]	Magnoni F，Colleoni M，Mattar D，et al. Contralateral Axillary Lymph Node Metastases from Breast Carcinoma：Is it Time to Review TNM Cancer Staging？［J］. Ann Surg Oncol，2020，27（11）：4488-4499.
[39]	Ai X，Wang M，Li J，et al. Supraclavicular lymph node dissection with radiotherapy versus radiotherapy alone for operable breast cancer with synchronous ipsilateral supraclavicular lymph node metastases：a real-world cohort study［J］. Gland Surg，2020，9（2）：329-341.
[40]	张薇，齐晓敏，陈翱翔，等. 锁上淋巴结清扫在初诊伴锁上淋巴结转移乳腺癌患者治疗中的作用［J］. 中华肿瘤杂志，2017，39（05）：374-379.
[41]	Gnerlich J，Jeffe DB，Deshpande AD，et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer：analysis of the 1988-2003 SEER data［J］. Ann Surg Oncol，2007，14（8）：2187-2194.
[42]	Khan SA，Stewart AK，Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer？［J］. Surgery，2002，132（4）：620-626；discussion 6-7.
[43]	Lian CL，Guo LY，Zhang L，et al. Aggressive Local Treatment Improves Survival in Stage Ⅳ Breast Cancer With Synchronous Metastasis［J］. Front Oncol，2020，10：522580.
[44]	Pons-Tostivint E，Kirova Y，Lusque A，et al. Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis［J］. Radiother Oncol，2020，145：109-116.
[45]	Viani GA，Gouveia AG，Louie AV，et al. Stereotactic body radiotherapy to treat breast cancer oligometastases：A systematic review with meta-analysis［J］. Radiother Oncol，2021，164：245-250.
[46]	向泓雨，刘荫华. 制定高质量临床实践指南推动中国乳腺外科诊治规范化进程［J/CD］. 中华普外科手术学杂志（电子版），2022，16（02）：119-122.
[47]	张毅，万安第. 开展中国乳腺外科腔镜手术多中心研究的思考［J/CD］. 中华普外科手术学杂志（电子版），2022，16（02）：127-131.

Please choose a citation manager

Content to export